文献速递血栓与止血淋巴瘤

系统性红斑狼疮合并抗磷脂综合征患者在接受B细胞淋巴瘤抗CD19嵌合抗原受体T细胞治疗后抗磷脂抗体消失

Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome.
PubMed 文献 · J Thromb Haemost · 2024-10-10

本文报告一例系统性红斑狼疮合并抗磷脂综合征、三重抗磷脂抗体阳性并反复深静脉血栓的女性患者,在接受靶向CD19的嵌合抗原受体T细胞治疗侵袭性B细胞淋巴瘤后,观察到3种抗磷脂抗体亚型持续消失,提示靶向抗CD19的免疫治疗在促血栓性自身免疫病中可能具有前景。

要点

  • 系统性红斑狼疮合并抗磷脂综合征患者三重抗磷脂抗体阳性,反复深静脉血栓。
  • 接受抗CD19 CAR-T治疗B细胞淋巴瘤后,3种抗磷脂抗体亚型持续消失。
  • 作者认为靶向抗CD19的免疫治疗在促血栓性自身免疫病中可能具有前景。

核心结论

  • 作者认为靶向抗CD19的免疫治疗在促血栓性自身免疫病中可能具有前景。

研究设计与样本

  • 个案报告:一例系统性红斑狼疮合并抗磷脂综合征、三重抗磷脂抗体阳性并反复深静脉血栓的女性患者。

主要发现

  • 患者在接受针对侵袭性B细胞淋巴瘤的嵌合抗原受体T细胞治疗后,3种抗磷脂抗体亚型均持续消失。

关键数值与推荐

  • 抗磷脂综合征表现为持续抗磷脂抗体阳性下自发静脉、动脉或微血管血栓和/或妊娠相关并发症。

临床怎么用

  • 目前最先进的治疗为长期维生素K拮抗剂抗凝以预防血栓事件复发,但仅为症状控制。
  • 迄今尚无永久清除抗磷脂抗体或针对 underlying pathomechanism 的治愈手段。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antiphospholipid syndrome is an autoimmune disorder characterized by the development of spontaneous venous, arterial, or microvascular thrombosis and/or pregnancy-related complications (eg, miscarriages, fetal loss) in the presence of persistent antiphospholipid (aPL) antibodies. Current state-of-the-art treatment consists of indefinite anticoagulation with vitamin K antagonists to prevent recurrence of thrombotic events. This, however, represents only a symptom-control-oriented treatment approach. To date, no curative option eradicating aPL antibodies permanently or addressing the underlying pathomechanism has been established. Here, we report the case of a woman with systemic lupus erythematosus and antiphospholipid syndrome with triple aPL antibody-positivity who developed recurrent deep venous thrombosis. After receiving chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma, sustained eradication of all 3 aPL antibody subtypes was observed, suggesting a promising role of immunotherapies targeting anti-CD19 for the treatment of prothrombotic autoimmune disorders.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Friedberg E, Wohlfarth P, Schiefer AI, et al. Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost. 2024. PMID: 39393780. doi:10.1016/j.jtha.2024.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。